Monoacylglycerol lipase

Class of enzymes From Wikipedia, the free encyclopedia

Monoacylglycerol lipase (EC 3.1.1.23; systematic name glycerol-ester acylhydrolase, also known as MAG lipase, acylglycerol lipase, MAGL, MGL or MGLL) is an enzyme that, in humans, is encoded by the MGLL gene.[1][2][3] MAGL is a 33-kDa, membrane-associated member of the serine hydrolase superfamily and contains the classical GXSXG consensus sequence common to most serine hydrolases. The catalytic triad has been identified as Ser122, His269, and Asp239.[2][4]

Human monoacylglycerol lipase
Quick facts acylglycerol lipase, Identifiers ...
acylglycerol lipase
Reaction catalyzed by MGLL, in which a free fatty acid (FFA) is released from a monoacylglycerol (MAG)
Identifiers
EC no.3.1.1.23
CAS no.9040-75-9
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
Gene OntologyAmiGO / QuickGO
Search
PMCarticles
PubMedarticles
NCBIproteins
Close
Quick facts monoglyceride lipase, Identifiers ...
monoglyceride lipase
Identifiers
SymbolMGLL
NCBI gene11343
HGNC17038
OMIM609699
RefSeqNM_007283
UniProtQ99685
Other data
EC number3.1.1.23
LocusChr. 3 p13-q13.33
Search for
StructuresSwiss-model
DomainsInterPro
Close

Function

Monoacylglycerol lipase catalyzes a reaction that uses water molecules to break the glycerol monoesters of long-chain fatty acids:

hydrolyses glycerol monoesters of long-chain fatty acids

It functions together with hormone-sensitive lipase (LIPE) to hydrolyze intracellular triglyceride stores in adipocytes and other cells to fatty acids and glycerol. MGLL may also complement lipoprotein lipase (LPL) in completing hydrolysis of monoglycerides resulting from degradation of lipoprotein triglycerides.[5]

Monoacylglycerol lipase is a key enzyme in the hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG).[6][7] It converts monoacylglycerols to the free fatty acid and glycerol. The contribution of MAGL to total brain 2-AG hydrolysis activity has been estimated to be ~85% (ABHD6 and ABHD12 are responsible for ~4% and ~9%, respectively, of the remainder),[8][9] and this in vitro estimate has been confirmed in vivo by the selective MAGL inhibitor JZL184.[10] Chronic inactivation of MAGL results in massive (>10-fold) elevations of brain 2-AG in mice, along with marked compensatory downregulation of CB1 receptors in selective brain areas.[11]

Inhibitors

MAGL enzyme inhibitors, for instance URB-602, URB-754, and JZL-184, produce cannabinoid-like behavioral effects in mice.[10]

Further examples include:[12]

  • KML-29
  • JZL-195 – dual MAGL and FAAH inhibitor
  • JW-642

As well as the following compounds which are under pharmaceutical development:

See also

References

Related Articles

Wikiwand AI